Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are about pricing/cost estimation and general treatment use; these are not supported or contradicted by the provided cyclosporine systemic prescribing information excerpts. A few safety/monitoring statements are directionally consistent with label warnings, but overall alignment is poor because the majority of claims cannot be verified from the supplied label content.
Category Scores
Accurate Statements
Cyclosporine therapy can require monitoring.
Provided label excerpts state: “renal function must be monitored during therapy” and “Patients… require frequent monitoring of serum creatinine.”
Patients often need periodic blood tests as part of safe use.
Provided label excerpts state: “Patients… require frequent monitoring of serum creatinine.” (i.e., laboratory monitoring during therapy).
Cyclosporine therapy can include lab fees and clinician visits in addition to medication cost.
Supported only insofar as the label requires frequent monitoring (lab tests) and clinical management; the specific cost/fee assertion is not explicitly stated.
Unsupported Statements
Cyclosporine pricing for psoriasis depends on the product strength/formulation used.
No pricing/cost information is present in the supplied prescribing information excerpts.
Cyclosporine pricing for psoriasis depends on whether it is brand or generic.
No brand vs generic pricing information is present in the supplied prescribing information excerpts.
Cyclosporine pricing for psoriasis depends on the dose.
No pricing/cost or dose-cost relationship is present in the supplied prescribing information excerpts.
Cyclosporine pricing for psoriasis depends on the pharmacy.
No pharmacy-specific pricing information is present in the supplied prescribing information excerpts.
Cyclosporine for psoriasis is commonly dispensed as generic cyclosporine.
No dispensing frequency or market use information is present in the supplied prescribing information excerpts.
Generic cyclosporine is usually far lower in cost than brand versions.
No comparative cost statements are present in the supplied prescribing information excerpts.
Cyclosporine costs can vary by state.
No cost-by-geography information is present in the supplied prescribing information excerpts.
Cyclosporine costs can vary with insurance coverage.
No insurance/cost coverage information is present in the supplied prescribing information excerpts.
Cyclosporine costs can vary when paying cash.
No cash pricing information is present in the supplied prescribing information excerpts.
A practical way to estimate monthly out-of-pocket cost is to calculate total milligrams per month from the prescribed daily dose.
No out-of-pocket cost estimation method is present in the supplied prescribing information excerpts.
Monthly out-of-pocket cost can be estimated by checking pharmacy price for the specific strength used.
No cost estimation guidance is present in the supplied prescribing information excerpts.
Brand cyclosporine price is typically higher than generic cyclosporine.
No comparative price statements are present in the supplied prescribing information excerpts.
Out-of-pocket cost differences with generic cyclosporine can come from the exact capsule or liquid strength and package size.
No pricing component/pack size guidance is present in the supplied prescribing information excerpts.
Out-of-pocket cost differences with generic cyclosporine can come from insurance copay rules (tier placement and deductible status).
No insurance copay/deductible information is present in the supplied prescribing information excerpts.
Out-of-pocket cost differences with generic cyclosporine can come from pharmacy pricing differences, especially for cash pay.
No pricing-by-pharmacy/cash-payer information is present in the supplied prescribing information excerpts.
Cyclosporine is often used for short-term control of moderate-to-severe psoriasis.
Label excerpt provided states indication for severe plaque psoriasis with failure to systemic therapy; it does not support claims about typical short-term use patterns.
Cyclosporine is often used as a bridge while other long-term therapies take effect.
No “bridge therapy” use concept or typical treatment sequencing is present in the supplied prescribing information excerpts.
Total treatment cost is time-dependent.
No cost/time relationship is present in the supplied prescribing information excerpts.
Using cyclosporine fewer months lowers overall spending even if daily price is the same.
No cost/spending relationship is present in the supplied prescribing information excerpts.
Contradictions
Important Omissions
Dosage and administration for psoriasis (including dosing regimen details) were not evaluated because the provided label excerpts do not include dosing instructions. Claims referencing dose were made (e.g., pricing depends on dose) without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only potentially label-relevant safety statements are about monitoring and lab tests, which are supported by the provided excerpts. However, many other claims are non-label (pricing and typical duration/role in treatment) and therefore not verifiable from the prescribing information provided; they do not directly assert medical risk/care instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Large portion of the AI-generated content is pricing/cost estimation and typical-use/therapy-sequencing language that is not present in the supplied prescribing information excerpts, so it cannot be verified against the label.
Suggested Improvement
Restrict claims to label-supported content from the provided sections (e.g., psoriasis indication criteria and monitoring/lab needs) and omit pricing estimation and typical duration/bridge-therapy statements unless the prescribing information explicitly addresses them.